Datapoint: Skyrizi Scores Crohn’s Disease Nod

The FDA last week approved AbbVie’s Skyrizi for the treatment of moderately to severely active Crohn’s disease. It will be the first IL-23 inhibitor in the Crohn’s market basket. Skyrizi was first approved in April 2019 as a treatment for severe plaque psoriasis, an indication for which it currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. About 38% of insured lives have preferred access to Skyrizi, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/22/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today